

HISTONE DEACETYLASE INHIBITORS: EMERGING MARKETS



PHM163A
February 2014

Shalini Shahani Dewan
Project Analyst

ISBN: 1-56965-699-1

bcc | Research
Market Forecasting

BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481 USA
866-285-7215 (toll-free within the USA),
or (+1) 781-489-7301
www.bccresearch.com
information@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
STUDY OBJECTIVES	2
REASONS FOR DOING THIS STUDY	2
CONTRIBUTIONS OF THE STUDY AND FOR WHOM	3
SCOPE OF THE STUDY	3
METHODOLOGY	3
INFORMATION SOURCES	3
ABOUT THE AUTHOR	4
RELATED BCC RESEARCH REPORTS	5
BCC RESEARCH ONLINE SERVICES	5
DISCLAIMER	5
CHAPTER 2 EXECUTIVE SUMMARY	7
<i>SUMMARY TABLE GLOBAL HISTONE DEACETYLASE INHIBITOR MARKET BY REGION, THROUGH 2018 (\$ MILLIONS)</i>	8
<i>SUMMARY FIGURE GLOBAL HISTONE DEACETYLASE INHIBITOR MARKET BY REGION, 2011-2018 (\$ MILLIONS)</i>	8
CHAPTER 3 OVERVIEW	11
HISTONE DEACETYLASES AND HISTONE ACETYLASES	11
HISTONE DEACETYLASE INHIBITORS	11
MECHANISM OF ACTION	11
APPROVED HISTONE DEACETYLASE INHIBITORS	12
FUTURE ACTIVITIES	12
CLASSIFICATION	13
HISTONE DEACETYLASES	13
<i>TABLE 1 HISTONE DEACETYLASE CLASSIFICATION</i>	13
HISTONE DEACETYLASE INHIBITORS	13
Classical Histone Deacetylase Inhibitors	14
Hydroxamic Acid	14
<i>FIGURE 1 HYDROXAMIC ACID GENERAL STRUCTURE</i>	15
Trichostatin A	15
<i>FIGURE 2 TRICHOSTATIN A ACID STRUCTURE</i>	15
Cyclic Tetrapeptides and Depsipeptides	16
Trapoxin B	16
<i>FIGURE 3 TRAPOXIN B STRUCTURE</i>	17
Romidepsin	17
<i>FIGURE 4 ROMIDEPSIN STRUCTURE</i>	17
Benzamides	18
<i>FIGURE 5 BENZAMIDE STRUCTURE</i>	18
Aliphatic Acid Compounds	18
Valproic Acid	18
<i>FIGURE 6 VALPROIC ACID STRUCTURE</i>	19
Sodium Valproate	19
<i>FIGURE 7 SODIUM VALPROATE STRUCTURE</i>	20
Phenylbutyrate	20

TOPIC	PAGE NO.
Sodium Phenylbutyrate	20
<i>FIGURE 8 SODIUM PHENYLBUTERATE STRUCTURE</i>	20
Butyrates	21
Sodium Butyrate	21
<i>FIGURE 9 SODIUM BUTYRATE STRUCTURE</i>	21
Pivanex	22
<i>FIGURE 10 PIVANEX STRUCTURE</i>	23
Second-Generation Histone Deacetylase Inhibitors	23
Hydroxamic Acid Derivatives	23
Vorinostat	23
<i>FIGURE 11 VORINOSTAT STRUCTURE</i>	23
Belinostat	24
<i>FIGURE 12 BELINOSTAT STRUCTURE</i>	25
Dacinostat	25
<i>FIGURE 13 DACINOSTAT STRUCTURE</i>	25
Panobinostat	26
<i>FIGURE 14 PANOBINOSTAT STRUCTURE</i>	26
Givinostat	26
<i>FIGURE 15 GIVINOSTAT STRUCTURE</i>	26
Pracinostat	27
<i>FIGURE 16 PRACINOSTAT STRUCTURE</i>	27
Abexinostat Hydrochloride	28
<i>FIGURE 17 ABEXINOSTAT STRUCTURE</i>	28
Quisinostat	28
<i>FIGURE 18 QUISINOSTAT STRUCTURE</i>	29
Resminostat	29
<i>FIGURE 19 RESMINOSTAT STRUCTURE</i>	29
Benzamide Derivatives	30
Entinostat	30
<i>FIGURE 20 ENTINOSTAT STRUCTURE</i>	30
CI994	30
<i>FIGURE 21 CI994 STRUCTURE</i>	31
Mocetinostat	31
<i>FIGURE 22 MOCETINOSTAT STRUCTURE</i>	31
OTHER HISTONE DEACETYLASE INHIBITORS	32
ACETYLATION OF NON-HISTONE PROTEINS	32
EMERGING TARGETS	33
<i>TABLE 2 EMERGING TARGETS FOR HISTONE DEACETYLASES INHIBITORS, BY HDI CLASS</i>	33
CHAPTER 4 REGULATORY ASPECTS	42
VORINOSTAT	42
DOSING INFORMATION	42
Dose Modifications	43
SAFETY INFORMATION	43
Safety of Vorinostat in Specific Populations	44
ROMIDEPSIN	44
DOSING INFORMATION	44

TOPIC	PAGE NO.
Dose Modifications	44
Nonhematologic Toxicities Except Alopecia	44
Hematologic Toxicities	45
SAFETY INFORMATION	45
Safety of Romidepsin in Specific Populations	45
REGULATORY DEVELOPMENTS FOR HISTONE DEACETYLASE INHIBITORS	46
CHAPTER 5 NEW DEVELOPMENTS	50
TABLE 3 DEVELOPMENT STAGES FOR HISTONE DEACETYLASE INHIBITORS	51
TABLE 4 NEW DEVELOPMENTS IN THE RESEARCH PIPELINE FOR HISTONE DEACETYLASE INHIBITORS AS MONOTHERAPIES, OCTOBER 2013	52
TABLE 5 NEW DEVELOPMENTS IN THE RESEARCH PIPELINE FOR HISTONE DEACETYLASE INHIBITORS AS COMBINATION THERAPIES, OCTOBER 2013	54
TABLE 6 ONGOING TRIALS FOR MAJOR HISTONE DEACETYLASE INHIBITORS AS MONOTHERAPIES AND COMBINATION THERAPIES, OCTOBER 2013	62
NEW COLLABORATIVE TRAILS AND FUTURE ACTIVITIES	63
CHAPTER 6 HISTONE DEACETYLASE INHIBITOR MARKET ANALYSIS	66
MARKET BY TYPE	67
TABLE 7 GLOBAL HISTONE DEACETYLASE INHIBITOR MARKET BY TYPE, THROUGH 2018 (\$ MILLIONS)	67
FIGURE 23 GLOBAL HISTONE DEACETYLASE INHIBITOR MARKET BY TYPE, 2011-2018 (\$ MILLIONS)	68
VORINOSTAT (ZOLINZA): HYDROXAMIC ACID DERIVATIVE	68
Market Overview	68
Market Revenue	69
TABLE 8 GLOBAL VORINSTAT MARKET BY REGION, THROUGH 2018 (\$ MILLIONS)	70
FIGURE 24 GLOBAL VORINSTAT MARKET BY REGION, 2011-2018 (\$ MILLIONS)	70
ROMIDEPSIN (ISTODAX): CYCLIC TETRAPEPTIDES AND DESPEPTIDES	70
Market Overview	71
Market Revenue	71
TABLE 9 GLOBAL ROMIDEPSIN MARKET BY REGION, THROUGH 2018 (\$ MILLIONS)	72
FIGURE 25 GLOBAL ROMIDEPSIN MARKET BY REGION, 2011-2018 (\$ MILLIONS)	72
MARKET SHARE	72
TABLE 10 HISTONE DEACETYLASE INHIBITOR MARKET SHARE BY TYPE, 2012 (%)	73
FIGURE 26 HISTONE DEACETYLASE INHIBITOR MARKET SHARE BY TYPE, 2012 (%)	73
MARKET BY REGION	73
MARKET OVERVIEW	73
MARKET REVENUE	75
TABLE 11 HISTONE DEACETYLASE INHIBITOR MARKET BY REGION, THROUGH 2018 (\$ MILLIONS)	76
FIGURE 27 HISTONE DEACETYLASE INHIBITOR MARKET BY REGION, 2011-2018 (\$ MILLIONS)	76
MARKET SHARE	76
TABLE 12 HISTONE DEACETYLASE INHIBITOR MARKET SHARE BY REGION, 2012 (\$ MILLIONS)	77
FIGURE 28 HISTONE DEACETYLASE INHIBITOR MARKET SHARE BY REGION, 2012 (\$ MILLIONS)	77
PROSPECTIVE FUTURE HISTONE DEACETYLASE INHIBITORS MARKET	77

TOPIC	PAGE NO.
INDUSTRY STRUCTURE	78
TABLE 13 LEADING HISTONE DEACETYLASE INHIBITOR MANUFACTURERS AND SUPPLIERS BY TYPE	78
MARKET SHARES	79
TABLE 14 HISTONE DEACETYLASE INHIBITOR MANUFACTURERS BY MARKET SHARE, 2012 (%)	79
FIGURE 29 HISTONE DEACETYLASE INHIBITOR MANUFACTURERS BY MARKET SHARE, 2012 (%)	80
CHAPTER 7 MARKET BY APPLICATION	82
TABLE 15 HISTONE DEACETYLASE INHIBITOR TYPES BY APPLICATION	82
TABLE 16 HISTONE DEACETYLASE INHIBITOR COMBINATIONS WITH THERAPIES BY APPLICATION	83
MARKET BY APPLICATION	84
CUTANEOUS T-CELL LYMPHOMAS	84
PERIPHERAL T-CELL LYMPHOMAS	84
MARKET OVERVIEW	85
MARKET REVENUE	86
TABLE 17 GLOBAL HISTONE DEACETYLASE INHIBITOR MARKET BY DISEASE TYPE, THROUGH 2018 (\$ MILLIONS)	87
FIGURE 30 GLOBAL HISTONE DEACETYLASE INHIBITOR MARKET BY DISEASE TYPE, 2011-2018 (\$ MILLIONS)	87
MARKET SHARE	88
TABLE 18 HISTONE DEACETYLASE INHIBITOR MARKET SHARE BY DISEASE TYPE, 2012 (%)	88
FIGURE 31 HISTONE DEACETYLASE INHIBITOR MARKET SHARE BY DISEASE TYPE, 2012 (%)	88
PROSPECTIVE APPLICATIONS FOR HISTONE DEACETYLASE INHIBITORS	88
CANCER	89
NEURODEGENERATIVE AND CENTRAL NERVOUS SYSTEM DISEASES	89
INFLAMMATORY DISEASES	90
CARDIAC AILMENTS	91
HIV AND AIDS	91
OTHERS	91
RESEARCH AND DEVELOPMENT	92
TABLE 19 HISTONE DEACETYLASE INHIBITOR FUNDING (\$ MILLIONS)	93
CHAPTER 8 PATENT ANALYSIS	95
PATENTS BY YEAR	96
TABLE 20 PATENTS GRANTED, 2011-OCTOBER 2013	96
FIGURE 32 PATENTS GRANTED, 2011-OCTOBER 2013	96
PATENTS BY HISTONE DEACETYLASE INHIBITOR CATEGORY	97
TABLE 21 HISTONE DEACETYLASE INHIBITOR PATENTS, 2011-OCTOBER 2013	97
FIGURE 33 HISTONE DEACETYLASE INHIBITOR PATENTS, 2011-OCTOBER 2013	98
PATENTS BY HISTONE DEACETYLASE INHIBITORS TYPE	98
PATENTS BY HYDROXAMIC ACID	98
TABLE 22 HYDROXAMIC ACID OR HYDROXAMATE PATENTS BY TYPE, 2011-OCTOBER 2013	99

TOPIC	PAGE NO.
<i>FIGURE 34 HYDROXAMIC ACID OR HYDROXAMATE PATENTS BY TYPE, 2011-OCTOBER 2013</i>	99
CYCLIC TETRAPEPTIDE AND DEPSIPEPTIDE PATENTS	100
<i>TABLE 23 CYCLIC TETRAPEPTIDE AND DEPSIPEPTIDE PATENTS BY TYPE, 2011-OCTOBER 2013</i>	100
BENZAMIDE PATENTS	100
<i>TABLE 24 BENZAMIDE PATENTS BY TYPE, 2011-OCTOBER 2013</i>	100
ALIPHATIC ACID COMPOUND PATENTS	101
<i>TABLE 25 ALIPHATIC ACID COMPOUND PATENTS BY TYPE, 2011-OCTOBER 2013</i>	101
OTHER HISTONE DEACETYLASE INHIBITOR PATENTS	101
<i>TABLE 26 OTHER HISTONE DEACETYLASE INHIBITOR PATENTS, 2011-OCTOBER 2013</i>	101
PATENTS BY COUNTRY	102
HYDROXAMIC ACID	102
<i>TABLE 27 HYDROXAMIC ACID OR HYDROXAMATE PATENTS BY COUNTRY, 2011-OCTOBER 2013</i>	102
<i>TABLE 28 HYDROXAMIC ACID OR HYDROXAMATES PATENT SHARES BY COUNTRY, 2011-OCTOBER 2013 (%)</i>	103
CYCLIC TETRAPEPTIDES AND DEPSIPEPTIDES	103
<i>TABLE 29 CYCLIC TETRAPEPTIDE AND DEPSIPEPTIDE PATENTS BY COUNTRY, 2011-OCTOBER 2013</i>	103
<i>TABLE 30 CYCLIC TETRAPEPTIDE AND DEPSIPEPTIDE PATENT SHARES BY COUNTRY, 2011-OCTOBER 2013 (%)</i>	104
BENZAMIDES	104
<i>TABLE 31 BENZAMIDE PATENTS BY COUNTRY, 2011-OCTOBER 2013</i>	104
<i>TABLE 32 BENZAMIDE PATENT SHARES BY COUNTRY, 2011-OCT 2013 (%)</i>	105
ALIPHATIC ACID COMPOUNDS	105
<i>TABLE 33 ALIPHATIC ACID COMPOUND PATENTS BY COUNTRY, 2011-OCTOBER 2013</i>	105
<i>TABLE 34 ALIPHATIC ACID COMPOUND PATENT SHARES BY COUNTRY, 2011-OCTOBER 2013 (%)</i>	106
OTHER HISTONE DEACETYLASE INHIBITORS	106
<i>TABLE 35 OTHER HISTONE DEACETYLASE INHIBITOR PATENTS BY COUNTRY, 2011-OCTOBER 2013</i>	106
<i>TABLE 36 OTHER HISTONE DEACETYLASE INHIBITOR PATENT SHARES BY COUNTRY, 2011-OCTOBER 2013 (%)</i>	107
PATENTS BY COMPANY	107
HYDROXAMIC ACIDS	107
<i>TABLE 37 HYDROXAMIC ACID OR HYDROXAMATE PATENTS BY COMPANY, 2011-OCTOBER 2013</i>	107
CYCLIC TETRAPEPTIDES AND DEPSIPEPTIDES	108
<i>TABLE 38 CYCLIC TETRAPEPTIDE AND DEPSIPEPTIDE PATENTS BY COMPANY, 2011-OCTOBER 2013</i>	108
BENZAMIDES	108
<i>TABLE 39 BENZAMIDE PATENTS BY COMPANY, 2011-OCTOBER 2013</i>	109
ALIPHATIC ACID COMPOUNDS	109
<i>TABLE 40 ALIPHATIC ACID COMPOUND PATENTS BY COMPANY, 2011-OCTOBER 2013</i>	109
OTHER HISTONE DEACETYLASE INHIBITORS	109

TOPIC	PAGE NO.
<i>TABLE 41 OTHER HISTONE DEACETYLASE INHIBITOR PATENTS BY COMPANY, 2011-OCTOBER 2013</i>	110
PATENTS BY ASSIGNEE	110
HYDROXAMIC ACIDS	110
<i>TABLE 42 HYDROXAMIC ACID OR HYDROXAMATE PATENTS BY ASSIGNEE, 2011-OCTOBER 2013</i>	110
CYCLIC TETRAPEPTIDES AND DEPSIPEPTIDES	111
<i>TABLE 43 CYCLIC TETRAPEPTIDE AND DEPSIPEPTIDE PATENTS BY ASSIGNEE, 2011-OCTOBER 2013</i>	111
BENZAMIDES	111
<i>TABLE 44 BENZAMIDE PATENTS BY ASSIGNEE, 2011-OCTOBER 2013</i>	111
ALIPHATIC ACID COMPOUNDS	112
<i>TABLE 45 ALIPHATIC ACID COMPOUND PATENTS BY ASSIGNEE, 2011-OCTOBER 2013</i>	112
OTHER HISTONE DEACETYLASE INHIBITORS	112
<i>TABLE 46 OTHER HISTONE DEACETYLASE INHIBITOR PATENTS BY ASSIGNEE, 2011-OCTOBER 2013</i>	112
CHAPTER 9 CURRENT SITUATION	114
RESEARCH AND PROGRESS	114
NEW TECHNOLOGIES AND PLATFORMS IN HISTONE DEACETYLASE DEVELOPMENT	115
CANCERNAV	115
CHEMOGENOMIC-BASED DISCOVERY PLATFORM	115
ESTERASE-SENSITIVE MOTIF TECHNOLOGY	115
BIOLUMINESCENT HISTONE DEACETYLASE ASSAY	116
FACTORS AFFECTING THE HISTONE DECAETYLASE MARKET	116
CURRENT DRIVERS OF HISTONE DEACETYLASE MARKET	116
COLLABORATIONS AND ACQUISITIONS	117
CHAPTER 10 COMPANY PROFILES	120
4SC	120
ACETYLON PHARMACEUTICALS INC.	122
ARNO THERAPEUTICS INC.	124
ASAN MEDICAL CENTER	124
ASTELLAS PHARMA INC.	125
ASTRAZENECA PLC	126
CELGENE CORPORATION	127
CELLCEUTIX CORPORATION	128
CELLERON THERAPEUTICS LTD.	129
CHROMA THERAPEUTICS LTD.	130
COLUMBIA UNIVERSITY	130
CRYSTALGENOMICS INC.	131
CURIS INC.	131
CYCLACEL PHARMACEUTICALS	133
CYCLEX CO. LTD.	133
DIAXONHIT GROUP	134
ENVIVO PHARMACEUTICALS	134
GENENTECH INC.	135

TOPIC	PAGE NO.
GEORGETOWN UNIVERSITY	135
GEORGIA TECH RESEARCH CORP.	136
GILEAD SCIENCES INC.	136
IMPERIAL INNOVATIONS LTD.	137
ITALFARMACO S.P.A.	138
JANSSEN PHARMACEUTICA NV	138
KARUS THERAPEUTICS LIMITED	139
LES LABORATOIRES SERVIER	139
LIXTE BIOTECHNOLOGY HOLDINGS INC.	140
MAYO CLINIC	140
MEI PHARMA INC	141
MEMORIAL SLOAN-KETTERING CANCER CENTER	142
MERCK & CO. INC.	142
MIRATI THERAPEUTICS	143
NATIONAL CANCER INSTITUTE	144
NATIONAL COMPREHENSIVE CANCER NETWORK	145
NATUREWISE BIOTECH & MEDICALS CORPORATION	145
NOVARTIS INTERNATIONAL AG	146
OCEANYX PHARMACEUTICALS INC.	147
OHIO STATE UNIVERSITY COMPREHENSIVE CANCER CENTER	147
ONCOLYS BIOPHARMA INC.	148
PFIZER	148
PHARMACYCLICS	149
PROMEGA CORPORATION	149
REPLIGEN CORPORATION	150
ROSWELL PARK CANCER INSTITUTE	151
SHAPE PHARMACEUTICALS	152
SHENZHEN CHIPSCREEN BIOSCIENCES	153
SPECTRUM PHARMACEUTICALS	154
SYNDAX PHARMACEUTICALS INC.	155
TITAN PHARMACEUTICALS INC.	156
TOPOTARGET A/S	156
UNIVERSITY OF ILLINOIS: OFFICE OF TECHNOLOGY MANAGEMENT	157
UNIVERSITY OF SOUTHAMPTON HIGHFIELD	158
UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER	159
YAKULT HONSHA CO. LTD.	160
CHAPTER 11 ABBREVIATIONS	162

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE GLOBAL HISTONE DEACETYLASE INHIBITOR MARKET BY REGION, THROUGH 2018 (\$ MILLIONS)	8
TABLE 1 HISTONE DEACETYLASE CLASSIFICATION	13
TABLE 2 EMERGING TARGETS FOR HISTONE DEACETYLASES INHIBITORS, BY HDI CLASS	33
TABLE 3 DEVELOPMENT STAGES FOR HISTONE DEACETYLASE INHIBITORS	51
TABLE 4 NEW DEVELOPMENTS IN THE RESEARCH PIPELINE FOR HISTONE DEACETYLASE INHIBITORS AS MONOTHERAPIES, OCTOBER 2013	52
TABLE 5 NEW DEVELOPMENTS IN THE RESEARCH PIPELINE FOR HISTONE DEACETYLASE INHIBITORS AS COMBINATION THERAPIES, OCTOBER 2013	54
TABLE 6 ONGOING TRIALS FOR MAJOR HISTONE DEACETYLASE INHIBITORS AS MONOTHERAPIES AND COMBINATION THERAPIES, OCTOBER 2013	62
TABLE 7 GLOBAL HISTONE DEACETYLASE INHIBITOR MARKET BY TYPE, THROUGH 2018 (\$ MILLIONS)	67
TABLE 8 GLOBAL VORINSTAT MARKET BY REGION, THROUGH 2018 (\$ MILLIONS)	70
TABLE 9 GLOBAL ROMIDEPSIN MARKET BY REGION, THROUGH 2018 (\$ MILLIONS)	72
TABLE 10 HISTONE DEACETYLASE INHIBITOR MARKET SHARE BY TYPE, 2012 (%)	73
TABLE 11 HISTONE DEACETYLASE INHIBITOR MARKET BY REGION, THROUGH 2018 (\$ MILLIONS)	76
TABLE 12 HISTONE DEACETYLASE INHIBITOR MARKET SHARE BY REGION, 2012 (\$ MILLIONS)	77
TABLE 13 LEADING HISTONE DEACETYLASE INHIBITOR MANUFACTURERS AND SUPPLIERS BY TYPE	78
TABLE 14 HISTONE DEACETYLASE INHIBITOR MANUFACTURERS BY MARKET SHARE, 2012 (%)	79
TABLE 15 HISTONE DEACETYLASE INHIBITOR TYPES BY APPLICATION	82
TABLE 16 HISTONE DEACETYLASE INHIBITOR COMBINATIONS WITH THERAPIES BY APPLICATION	83
TABLE 17 GLOBAL HISTONE DEACETYLASE INHIBITOR MARKET BY DISEASE TYPE, THROUGH 2018 (\$ MILLIONS)	87
TABLE 18 HISTONE DEACETYLASE INHIBITOR MARKET SHARE BY DISEASE TYPE, 2012 (%)	88
TABLE 19 HISTONE DEACETYLASE INHIBITOR FUNDING (\$ MILLIONS)	93
TABLE 20 PATENTS GRANTED, 2011-OCTOBER 2013	96
TABLE 21 HISTONE DEACETYLASE INHIBITOR PATENTS, 2011-OCTOBER 2013	97
TABLE 22 HYDROXAMIC ACID OR HYDROXAMATE PATENTS BY TYPE, 2011-OCTOBER 2013	99
TABLE 23 CYCLIC TETRAPEPTIDE AND DEPSIPEPTIDE PATENTS BY TYPE, 2011-OCTOBER 2013	100
TABLE 24 BENZAMIDE PATENTS BY TYPE, 2011-OCTOBER 2013	100
TABLE 25 ALIPHATIC ACID COMPOUND PATENTS BY TYPE, 2011-OCTOBER 2013	101
TABLE 26 OTHER HISTONE DEACETYLASE INHIBITOR PATENTS, 2011-OCTOBER 2013	101
TABLE 27 HYDROXAMIC ACID OR HYDROXAMATE PATENTS BY COUNTRY, 2011-OCTOBER 2013	102
TABLE 28 HYDROXAMIC ACID OR HYDROXAMATES PATENT SHARES BY COUNTRY, 2011-OCTOBER 2013 (%)	103
TABLE 29 CYCLIC TETRAPEPTIDE AND DEPSIPEPTIDE PATENTS BY COUNTRY, 2011-OCTOBER 2013	103
TABLE 30 CYCLIC TETRAPEPTIDE AND DEPSIPEPTIDE PATENT SHARES BY COUNTRY, 2011-OCTOBER 2013 (%)	104

TABLE HEADING	PAGE NO.
TABLE 31 BENZAMIDE PATENTS BY COUNTRY, 2011-OCTOBER 2013	104
TABLE 32 BENZAMIDE PATENT SHARES BY COUNTRY, 2011-OCT 2013 (%)	105
TABLE 33 ALIPHATIC ACID COMPOUND PATENTS BY COUNTRY, 2011-OCTOBER 2013	105
TABLE 34 ALIPHATIC ACID COMPOUND PATENT SHARES BY COUNTRY, 2011-OCTOBER 2013 (%)	106
TABLE 35 OTHER HISTONE DEACETYLASE INHIBITOR PATENTS BY COUNTRY, 2011-OCTOBER 2013	106
TABLE 36 OTHER HISTONE DEACETYLASE INHIBITOR PATENT SHARES BY COUNTRY, 2011-OCTOBER 2013 (%)	107
TABLE 37 HYDROXAMIC ACID OR HYDROXAMATE PATENTS BY COMPANY, 2011-OCTOBER 2013	107
TABLE 38 CYCLIC TETRAPEPTIDE AND DEPSIPEPTIDE PATENTS BY COMPANY, 2011-OCTOBER 2013	108
TABLE 39 BENZAMIDE PATENTS BY COMPANY, 2011-OCTOBER 2013	109
TABLE 40 ALIPHATIC ACID COMPOUND PATENTS BY COMPANY, 2011-OCTOBER 2013	109
TABLE 41 OTHER HISTONE DEACETYLASE INHIBITOR PATENTS BY COMPANY, 2011-OCTOBER 2013	110
TABLE 42 HYDROXAMIC ACID OR HYDROXAMATE PATENTS BY ASSIGNEE, 2011-OCTOBER 2013	110
TABLE 43 CYCLIC TETRAPEPTIDE AND DEPSIPEPTIDE PATENTS BY ASSIGNEE, 2011-OCTOBER 2013	111
TABLE 44 BENZAMIDE PATENTS BY ASSIGNEE, 2011-OCTOBER 2013	111
TABLE 45 ALIPHATIC ACID COMPOUND PATENTS BY ASSIGNEE, 2011-OCTOBER 2013	112
TABLE 46 OTHER HISTONE DEACETYLASE INHIBITOR PATENTS BY ASSIGNEE, 2011-OCTOBER 2013	112

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE GLOBAL HISTONE DEACETYLASE INHIBITOR MARKET BY REGION, 2011-2018 (\$ MILLIONS)	8
FIGURE 1 HYDROXAMIC ACID GENERAL STRUCTURE	15
FIGURE 2 TRICHOSTATIN A ACID STRUCTURE	15
FIGURE 3 TRAPOXIN B STRUCTURE	17
FIGURE 4 ROMIDEPSIN STRUCTURE	17
FIGURE 5 BENZAMIDE STRUCTURE	18
FIGURE 6 VALPROIC ACID STRUCTURE	19
FIGURE 7 SODIUM VALPROATE STRUCTURE	20
FIGURE 8 SODIUM PHENYLBUTERATE STRUCTURE	20
FIGURE 9 SODIUM BUTYRATE STRUCTURE	21
FIGURE 10 PIVANEX STRUCTURE	23
FIGURE 11 VORINOSTAT STRUCTURE	23
FIGURE 12 BELINOSTAT STRUCTURE	25
FIGURE 13 DACINOSTAT STRUCTURE	25
FIGURE 14 PANOBINOSTAT STRUCTURE	26
FIGURE 15 GIVINOSTAT STRUCTURE	26
FIGURE 16 PRACINOSTAT STRUCTURE	27
FIGURE 17 ABEXINOSTAT STRUCTURE	28
FIGURE 18 QUISINOSTAT STRUCTURE	29
FIGURE 19 RESMINOSTAT STRUCTURE	29
FIGURE 20 ENTINOSTAT STRUCTURE	30
FIGURE 21 CI994 STRUCTURE	31
FIGURE 22 MOCETINOSTAT STRUCTURE	31
FIGURE 23 GLOBAL HISTONE DEACETYLASE INHIBITOR MARKET BY TYPE, 2011-2018 (\$ MILLIONS)	68
FIGURE 24 GLOBAL VORINSTAT MARKET BY REGION, 2011-2018 (\$ MILLIONS)	70
FIGURE 25 GLOBAL ROMIDEPSIN MARKET BY REGION, 2011-2018 (\$ MILLIONS)	72
FIGURE 26 HISTONE DEACETYLASE INHIBITOR MARKET SHARE BY TYPE, 2012 (%)	73
FIGURE 27 HISTONE DEACETYLASE INHIBITOR MARKET BY REGION, 2011-2018 (\$ MILLIONS)	76
FIGURE 28 HISTONE DEACETYLASE INHIBITOR MARKET SHARE BY REGION, 2012 (\$ MILLIONS)	77
FIGURE 29 HISTONE DEACETYLASE INHIBITOR MANUFACTURERS BY MARKET SHARE, 2012 (%)	80
FIGURE 30 GLOBAL HISTONE DEACETYLASE INHIBITOR MARKET BY DISEASE TYPE, 2011-2018 (\$ MILLIONS)	87
FIGURE 31 HISTONE DEACETYLASE INHIBITOR MARKET SHARE BY DISEASE TYPE, 2012 (%)	88
FIGURE 32 PATENTS GRANTED, 2011-OCTOBER 2013	96
FIGURE 33 HISTONE DEACETYLASE INHIBITOR PATENTS, 2011-OCTOBER 2013	98
FIGURE 34 HYDROXAMIC ACID OR HYDROXAMATE PATENTS BY TYPE, 2011-OCTOBER 2013	99